Researchers Create Organoids that Model BRCA-Positive Ovarian Cancer

A liquid biopsy test has detected changes in the BRCA1 or BRCA2 genes associated with ovarian and breast cancer that signal when the disease stops responding to treatment through platinum chemotherapy or poly ADP-ribose polymerase (PARP) inhibitors. [Source: © freshidea/Fotolia]

Stem cell scientists have created fallopian tube-based organoids that may help predict which individuals with BRCA-1 mutations will develop ovarian cancer years or even decades in advance, and could be used to develop personalized therapies.

 

Their study was published this week in Cell Reports. Clive Svendsen, Ph.D., professor of Biomedical Sciences and Medicine at Cedars-Sinai is co-corresponding author of the study. The other co-corresponding author is Beth Karlan, MD, professor of Obstetrics and Gynecology in the David Geffen School of Medicine at UCLA.

 

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S., in part because symptoms are often subtle and most tumors elude detection until they are in advanced stages and have spread past the ovaries. While the lifetime risk of developing ovarian cancer is less than 2% for the general female population, the estimated risk for women who carry a mutation in the BRCA-1 gene is between 35% and 70%, according to the American Cancer Society.

 

Faced with such steep odds, some women with BRCA-1 mutations choose to have their breasts or ovaries and fallopian tubes surgically removed even though they may never develop cancers in these tissues. The findings could help physicians pinpoint which of these women are most likely to develop ovarian cancer in the future—and which are not—and pursue new ways to block the process or treat the cancer. Unfortunately, no current human models exist for the disease initiation and progression.

 

“We created these fallopian organoids using cells from women with BRCA-1 mutations who had ovarian cancer,” explained Svendsen, executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute. “Our data supports recent research indicating that ovarian cancer in these patients actually begins with cancerous lesions in the fallopian tube linings. If we can detect these abnormalities at the outset, we may be able to short-circuit the ovarian cancer.”

 

The team generated induced pluripotent stem cells (IPSCs), which can produce any type of cell. They started with blood samples taken from two groups of women: young ovarian cancer patients who had the BRCA-1 mutation and a control group of healthy women. Investigators then used the iPSCs to produce organoids modeling the lining of fallopian tubes and compared the organoids in the two groups.

 

“We were surprised to find multiple cellular pathologies consistent with cancer development only in the organoids from the BRCA-1 patients,” said Nur Yucer, PhD, project scientist in Svendsen’s lab and first author of the Cell Reports study. “Organoids derived from women with the most aggressive ovarian cancer displayed the most severe organoid pathology.”

 

Besides showing how ovarian cancer is “seeded” in the fallopian tubes of women with mutated BRCA-1, the organoid technology potentially can be used to determine if a drug might work against the disease in an individual, Svendsen said. Each organoid carries the genes of the person who provided the blood sample, making it a “twin” of that person’s own fallopian tube linings. Multiple drugs can be tested on the organoids without exposing the patient to them.

 

“This study represents an exciting use of IPSCs, bringing us closer than ever to significantly improving the outcomes for women with this common type of ovarian cancer,” said Jeffrey Golden, MD, vice dean of Research and Graduate Education and director of the Burns and Allen Research Institute at Cedars-Sinai. “Building on these findings may one day allow us to provide early, lifesaving detection of ovarian cancer in women who carry the BRCA-1 mutation and create effective, individualized prevention and, if necessary, treatment strategies.

This site uses Akismet to reduce spam. Learn how your comment data is processed.